Scarica l'app Stockscreener
1.26
1.56%
-0.02
Dopo l'orario di chiusura:
1.25
-0.01
-0.79%
Precedente Chiudi:
$1.28
Aprire:
$1.31
Volume 24 ore:
596.11K
Relative Volume:
0.07
Capitalizzazione di mercato:
$8.70M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.9545
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
-7.35%
1M Prestazione:
+68.43%
6M Prestazione:
+83.35%
1 anno Prestazione:
-7.35%
Intervallo 1D:
$1.2291
$1.35
Intervallo di 1 settimana:
$1.20
$1.35
Portata 52W:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Nome
Hoth Therapeutics Inc
Settore
Industria
Telefono
(646)756-2997
Indirizzo
590 MADISON AVENUE, NEW YORK, NY
Confronta HOTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.26 | 8.70M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-10-15 | Iniziato | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World
Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Hoth Therapeutics expands cancer drug patent portfolio - MSN
Hoth Therapeutics Breaks New Ground! Nasdaq Compliance Achieved! - Mi Valle
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
Hoth Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com Australia
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications - PR Newswire
Hoth Therapeutics Expands Cancer Drug Patent Portfolio, Strengthens HT-001 Development Strategy - StockTitan
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries - PR Newswire
S&P 500 E-Mini (ESM23) Quote - The Globe and Mail
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited - Asianet Newsable
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
Dow Jones Global (DOWG) QuotePress Release - The Globe and Mail
Hoth reports 100% success in cancer skin toxicity trial By Investing.com - Investing.com South Africa
Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients - Mugglehead
Hoth Therapeutics stock hits 52-week high at $1.73 By Investing.com - Investing.com Australia
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
PHLX Euro FX (XDE) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success - Yahoo Finance
Why Hoth Therapeutics Inc Stock Might Make Sense If Bought Today - Stocks Register
Stock market news: Hoth Therapeutics +184.32%, DatChat +79.85% among top gainers during mid day trading - Business Upturn
Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn
Nasdaq Down 1.5%; RPM Posts Upbeat Results - Benzinga
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday? - Benzinga
Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment - MarketWatch
Stock market today: XTI Aerospace surged by 108.52% while ACELYRIN posted fall of 38.68% in early trading - Business Upturn
Dow Surges Over 100 Points; US Trade Deficit Widens In November - Benzinga
Hoth Therapeutics stock hits 52-week high at $1.73 - Investing.com
Hoth reports 100% success in cancer skin toxicity trial - Investing.com
Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):